Fulco van der Veen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fulco van der Veen has a total of 882 co-authors. Here are the top co-authors by number of shared publications:
- Ben W. J. Mol
Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, The Netherlands
12 shared publications S. Repping
Centre for Reproductive Medicine, Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, the Netherlands
9 shared publications- Madelon van Wely
Center for Reproductive Medicine, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam , Amsterdam
8 shared publications - Ben Willem Mol
Department of Obstetrics and Gynaecology Monash University Clayton Victoria Australia
4 shared publications - Norah M. van Mello
Department of Obstetrics and Gynaecology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
4 shared publications P.G.A. Hompes
Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
4 shared publications
Latest Publications
- 22 September 2016
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 31 (12) , 2665-2667
IUI and IVF for unexplained subfertility: where did we go wrong?
IUI is a first-line treatment for couples with unexplained or mild male subfertility and has become one of the most widely used fertility-enhancing treatments. The results of a recent trial comparing IVF to IUI, demonstrating similar live birth rates, have been used to build a case supporting the effectiveness of IUI. Yet, this conclusion might be somewhat premature, as the superiority of neither IUI nor IVF over no treatment has ever been proven. The evidence on the effectiveness and safety of IUI and IVF has been evaluated in two Cochrane reviews which both suggested that there is insufficient evidence to conclude that IUI or IVF is effective compared to sexual intercourse in couples with unexplained subfertility. Recommendations for clinical practice have been given in the most recent National Institute for Health and Care Excellence fertility guideline that advises not to offer IUI any longer and suggests 2 years of sexual intercourse followed by IVF. This recommendation has generated an ongoing debate, with only 4% of all gynecologists in the UK discontinuing the use of IUI. We feel that it is high time to provide proper scientific evidence for the effectiveness of IUI, or lack thereof, and invite the medical community to start RCTs comparing IUI to sexual intercourse.
- 22 September 2016
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 31 (12) , 2665-2667
IUI and IVF for unexplained subfertility: where did we go wrong?
IUI is a first-line treatment for couples with unexplained or mild male subfertility and has become one of the most widely used fertility-enhancing treatments. The results of a recent trial comparing IVF to IUI, demonstrating similar live birth rates, have been used to build a case supporting the effectiveness of IUI. Yet, this conclusion might be somewhat premature, as the superiority of neither IUI nor IVF over no treatment has ever been proven. The evidence on the effectiveness and safety of IUI and IVF has been evaluated in two Cochrane reviews which both suggested that there is insufficient evidence to conclude that IUI or IVF is effective compared to sexual intercourse in couples with unexplained subfertility. Recommendations for clinical practice have been given in the most recent National Institute for Health and Care Excellence fertility guideline that advises not to offer IUI any longer and suggests 2 years of sexual intercourse followed by IVF. This recommendation has generated an ongoing debate, with only 4% of all gynecologists in the UK discontinuing the use of IUI. We feel that it is high time to provide proper scientific evidence for the effectiveness of IUI, or lack thereof, and invite the medical community to start RCTs comparing IUI to sexual intercourse.
- 1 February 2014
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 28 (2) , 239-245
Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands
- 1 February 2014
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 28 (2) , 239-245
Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands
- Open Access
- 23 April 2013
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 28 (7) , 1737-1742
Economic analysis of chromosome testing in couples with recurrent miscarriage to prevent handicapped offspring
Which strategy is least expensive to prevent the birth of a handicapped child in couples with recurrent miscarriage (RM); parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents, or amniocentesis in all ongoing pregnancies without the knowledge of parental carrier status? For virtually all couples with RM amniocentesis in all ongoing pregnancies without the knowledge of parental carrier status is less expensive in preventing the birth of a handicapped child than parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents. One of the causes of RM is a balanced chromosome abnormality in one of the partners. If one of the partners is carrier of a balanced structural chromosomal abnormality, the risk of offspring with an unbalanced structural chromosome abnormality is increased. Like all couples, couples with RM also have an age-dependent risk for fetal aneuploidy, of which trisomy 21 is most common. Model-based economic analysis to compare costs and effects of two strategies in couples with RM to prevent the birth of a handicapped child in case of ongoing pregnancy. Comparison of two strategies in women with RM: strategy (I) parental chromosome analysis followed by amniocentesis in pregnancy in case of carrier status of one of the parents and strategy (II) amniocentesis in all ongoing pregnancies without the knowledge of carrier status. No testing was the reference strategy. Data on probabilities and costs were derived from the literature. Incremental costs and effects were calculated [incremental cost-effectiveness ratio (ICER)]. Effectiveness was expressed as the number of prevented births of handicapped child equivalents compared with no testing. In these calculations, the birth of a handicapped child was valued 10 times worse than the loss of a viable pregnancy due to amniocentesis. Depending on the risk for carrier status, the ICER for Strategy I (parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents) varied between €226 000 and €6 556 000 per prevented handicapped child equivalent. For Strategy II (amniocentesis in all ongoing pregnancies without the knowledge of carrier status), the ICER varied between €2000 and €233 000 per prevented handicapped child equivalent. Strategy I was less expensive than Strategy II only for a small subgroup of couples with maternal age <23 years, three or more previous miscarriages and a family history of RM. Our analysis is not a plea for amniocentesis in all women with RM. Individual risk assessment with serum markers and nuchal translucency is probably more effective at lower cost. This analysis can be used by clinicians to explain the chances of adverse pregnancy outcome in couples with RM, as well as by policy makers in health-care economics. Future guidelines on RM might be more restrictive from the perspective of the limited health-care resources that we have available. Supported by ZonMW. ZonMW had no role in designing the study, data collection, analysis and interpretation of data or writing of the report. Competing interests: none.
- 23 April 2013
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 28 (7) , 1737-1742
Open AccessEconomic analysis of chromosome testing in couples with recurrent miscarriage to prevent handicapped offspring
Which strategy is least expensive to prevent the birth of a handicapped child in couples with recurrent miscarriage (RM); parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents, or amniocentesis in all ongoing pregnancies without the knowledge of parental carrier status? For virtually all couples with RM amniocentesis in all ongoing pregnancies without the knowledge of parental carrier status is less expensive in preventing the birth of a handicapped child than parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents. One of the causes of RM is a balanced chromosome abnormality in one of the partners. If one of the partners is carrier of a balanced structural chromosomal abnormality, the risk of offspring with an unbalanced structural chromosome abnormality is increased. Like all couples, couples with RM also have an age-dependent risk for fetal aneuploidy, of which trisomy 21 is most common. Model-based economic analysis to compare costs and effects of two strategies in couples with RM to prevent the birth of a handicapped child in case of ongoing pregnancy. Comparison of two strategies in women with RM: strategy (I) parental chromosome analysis followed by amniocentesis in pregnancy in case of carrier status of one of the parents and strategy (II) amniocentesis in all ongoing pregnancies without the knowledge of carrier status. No testing was the reference strategy. Data on probabilities and costs were derived from the literature. Incremental costs and effects were calculated [incremental cost-effectiveness ratio (ICER)]. Effectiveness was expressed as the number of prevented births of handicapped child equivalents compared with no testing. In these calculations, the birth of a handicapped child was valued 10 times worse than the loss of a viable pregnancy due to amniocentesis. Depending on the risk for carrier status, the ICER for Strategy I (parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents) varied between €226 000 and €6 556 000 per prevented handicapped child equivalent. For Strategy II (amniocentesis in all ongoing pregnancies without the knowledge of carrier status), the ICER varied between €2000 and €233 000 per prevented handicapped child equivalent. Strategy I was less expensive than Strategy II only for a small subgroup of couples with maternal age <23 years, three or more previous miscarriages and a family history of RM. Our analysis is not a plea for amniocentesis in all women with RM. Individual risk assessment with serum markers and nuchal translucency is probably more effective at lower cost. This analysis can be used by clinicians to explain the chances of adverse pregnancy outcome in couples with RM, as well as by policy makers in health-care economics. Future guidelines on RM might be more restrictive from the perspective of the limited health-care resources that we have available. Supported by ZonMW. ZonMW had no role in designing the study, data collection, analysis and interpretation of data or writing of the report. Competing interests: none.
- 18 May 2012
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 119 (8) , 953-957
The prognostic profile of subfertile couples and treatment outcome after expectant management, intrauterine insemination and in vitro fertilisation: a study protocol for the meta‐analysis of individual patient data
Please cite this paper as: Boogaard N van den, Hompes P, Barnhart K, Bhattacharya S, Custers I, Coutifaris C, Goverde A, Guzick D, Litvak P, Steures P, Veen F van der, Bossuyt P, Mol B. The prognostic profile of subfertile couples and treatment outcome after expectant management, intrauterine insemination and in vitro fertilisation: a study protocol for the meta‐analysis of individual patient data. BJOG 2012;119:953–957. Objective The current evidence concerning the best treatment option for couples with unexplained and male subfertility is inconclusive. Most studies that have evaluated the effectiveness of treatment options, such as expectant management (EM), intrauterine insemination (IUI), with or without controlled ovarian stimulation (COS), and in vitro fertilisation (IVF), have not taken the couples’ prognosis into account. It is very likely that the individual prognosis of the couple influences the effect of treatment. Individual patient data analyses allow us to take these prognostic factors into account, and to evaluate their effect on treatment outcome. This study aims to use anonymised data from relevant published trials to perform an individual patient data meta‐analysis, evaluating the effect of couples’ prognosis on the effectiveness of EM, IUI, with or without COS, and IVF. Methods Based on earlier systematic reviews and an updated search, randomised controlled trials will be considered for inclusion. Untreated subfertile couples with unexplained or male subfertility included in trials comparing EM, IUI, with or without COS, and IVF are included. Authors of the included studies will be invited to share their original anonymised data. The data will be assessed on validity, quality and completeness. The prognosis of the individual couple will be calculated with existing prognostic models. The effect of the prognosis on treatment outcome will be analysed with marker‐by‐treatment predictiveness curves, illustrating the effect of prognosis on treatment outcome. This study is registered in PROSPERO (registration number CRD42011001832). Conclusion Ultimately, this study may help to select the appropriate fertility treatment, tailored to the needs of an individual couple.
- 18 May 2012
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 119 (8) , 953-957
The prognostic profile of subfertile couples and treatment outcome after expectant management, intrauterine insemination and in vitro fertilisation: a study protocol for the meta‐analysis of individual patient data
Please cite this paper as: Boogaard N van den, Hompes P, Barnhart K, Bhattacharya S, Custers I, Coutifaris C, Goverde A, Guzick D, Litvak P, Steures P, Veen F van der, Bossuyt P, Mol B. The prognostic profile of subfertile couples and treatment outcome after expectant management, intrauterine insemination and in vitro fertilisation: a study protocol for the meta‐analysis of individual patient data. BJOG 2012;119:953–957. Objective The current evidence concerning the best treatment option for couples with unexplained and male subfertility is inconclusive. Most studies that have evaluated the effectiveness of treatment options, such as expectant management (EM), intrauterine insemination (IUI), with or without controlled ovarian stimulation (COS), and in vitro fertilisation (IVF), have not taken the couples’ prognosis into account. It is very likely that the individual prognosis of the couple influences the effect of treatment. Individual patient data analyses allow us to take these prognostic factors into account, and to evaluate their effect on treatment outcome. This study aims to use anonymised data from relevant published trials to perform an individual patient data meta‐analysis, evaluating the effect of couples’ prognosis on the effectiveness of EM, IUI, with or without COS, and IVF. Methods Based on earlier systematic reviews and an updated search, randomised controlled trials will be considered for inclusion. Untreated subfertile couples with unexplained or male subfertility included in trials comparing EM, IUI, with or without COS, and IVF are included. Authors of the included studies will be invited to share their original anonymised data. The data will be assessed on validity, quality and completeness. The prognosis of the individual couple will be calculated with existing prognostic models. The effect of the prognosis on treatment outcome will be analysed with marker‐by‐treatment predictiveness curves, illustrating the effect of prognosis on treatment outcome. This study is registered in PROSPERO (registration number CRD42011001832). Conclusion Ultimately, this study may help to select the appropriate fertility treatment, tailored to the needs of an individual couple.
- 1 January 2012
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 27 (suppl 2) , ii84-ii86
SESSION 59: EMBRYOLOGY - DEVELOPMENT AND QUALITY
Introduction: Polar body analysis by array comparative genomic hybridisation (array CGH) has demonstrated a high incidence of errors in female meiosis resulting in aneuploidy in the oocytes and corresponding embryos of women of advanced maternal age undergoing in vitro fertilisation (IVF). These errors are predominantly caused by premature predivision of chromatids and there is a strong age related increase in the incidence of multiple aneuploidies which affect a majority of cells at cleavages stages. Here we have used non-invasive time-lapse imaging to measure the timing of the first and second cleavage divisions and the transition between the 2- and 4-cell stages and correlate these and other morphological parameters with the normal euploid chromosome copy number or the presence of single or multiple aneuploidies ascertained by cleavage stage biopsy at the 8-cell stage and single cell analysis by array CGH. A reliable, non-invasive, morphokinetic assessment that could distinguish between normal and aneuploid embryos would be a useful and cost effective tool in optimizing embryo selection for uterine transfer.
- 1 January 2012
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 27 (suppl 2) , ii84-ii86
SESSION 59: EMBRYOLOGY - DEVELOPMENT AND QUALITY
Introduction: Polar body analysis by array comparative genomic hybridisation (array CGH) has demonstrated a high incidence of errors in female meiosis resulting in aneuploidy in the oocytes and corresponding embryos of women of advanced maternal age undergoing in vitro fertilisation (IVF). These errors are predominantly caused by premature predivision of chromatids and there is a strong age related increase in the incidence of multiple aneuploidies which affect a majority of cells at cleavages stages. Here we have used non-invasive time-lapse imaging to measure the timing of the first and second cleavage divisions and the transition between the 2- and 4-cell stages and correlate these and other morphological parameters with the normal euploid chromosome copy number or the presence of single or multiple aneuploidies ascertained by cleavage stage biopsy at the 8-cell stage and single cell analysis by array CGH. A reliable, non-invasive, morphokinetic assessment that could distinguish between normal and aneuploid embryos would be a useful and cost effective tool in optimizing embryo selection for uterine transfer.
- 30 September 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 96 (3) , S272
Effect of age dependent embryo transfer policy on singleton and twin pregnancy outcomes after assisted reproductive technology
- 30 September 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 96 (3) , S272
Effect of age dependent embryo transfer policy on singleton and twin pregnancy outcomes after assisted reproductive technology
- 30 September 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 96 (3) , S140-S141
Timing of invasive diagnostic investigations for tubal pathology in the fertility work-up; a cost-effectiveness analysis
- 30 September 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 96 (3) , S140-S141
Timing of invasive diagnostic investigations for tubal pathology in the fertility work-up; a cost-effectiveness analysis
- 30 September 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 96 (3) , S263
Mild ovarian stimulation for women with poor ovarian response undergoing IVF/ICSI treatment cycles; randomized controlled study
- 30 September 2011
- Published by Elsevier in Fertility and Sterility
- Vol. 96 (3) , S263
Mild ovarian stimulation for women with poor ovarian response undergoing IVF/ICSI treatment cycles; randomized controlled study
- 31 August 2011
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 90 (2) , 149-150
Is severe maternal morbidity in ectopic pregnancy caused by patient related risk factors and/or by substandard care?
- 31 August 2011
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 90 (2) , 149-150
Is severe maternal morbidity in ectopic pregnancy caused by patient related risk factors and/or by substandard care?
- 16 July 2011
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 90 (2) , 181
Predictive value of serum hCG on the outcome of pregnancy of unknown location: a systematic review and meta-analysis
- 16 July 2011
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 90 (2) , 181
Predictive value of serum hCG on the outcome of pregnancy of unknown location: a systematic review and meta-analysis